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RESUmo
Este estudo teve como objetivos verifi-
car a adesão de portadores de transtorno 
afetivo bipolar (TAB) à terapêutica medica-
mentosa e identificar possíveis causas de 
adesão e não adesão ao medicamento de 
acordo com o perfil farmacoterapêutico. 
Trata-se de estudo transversal, descritivo, 
realizado em Núcleo de Saúde Mental de 
um município do interior paulista. Partici-
param do estudo 101 pacientes com TAB. 
Para coleta dos dados, utilizou-se a en-
trevista estruturada e o teste de Morisky-
-Green e, para a análise dos mesmos, o 
programa Statistical Package for the Social 
Science. Os resultados mostraram que a 
maioria (63%) dos sujeitos investigados 
não adere ao medicamento. Apesar de não 
ter ocorrido diferenças significativas entre 
o grupo de aderentes e não aderentes, 
para as variáveis investigadas, foi possível 
verificar a utilização de polifarmacoterapia 
e regimes terapêuticos complexos no trata-
mento do TAB. Permanece como desafio a 
implementação de estratégias que possam 
melhorar, na prática, a adesão de pacientes 
ao tratamento medicamentoso.
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ABStRAct
This cross-sectional and descriptive study 
aimed to verify the adherence of patients 
with Bipolar Affective Disorder (BAD) to 
medication and to identify possible causes 
of adherence and non-adherence to medi-
cation according to the pharmacothera-
peutic profile. The study was carried out in 
a mental health service in a city in the inte-
rior of the state of São Paulo. Participants 
included 101 patients with BAD. Struc-
tured interviews and the Morisky-Green 
test were used for data collection, and 
the Statistical Package for Social Science 
was employed for data analysis. Most sub-
jects (63%) did not adhere to medication. 
Although there were no significant differ-
ences between the adherent and non-ad-
herent groups for the researched variables, 
the use of polypharmacotherapy and com-
plex treatment regimens was observed in 
treatment for BAD. In practice, implement-
ing strategies to improve the adherence of 
patients to medication treatment remains 
a challenge.
dEScRiPtoRS 
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Medication adherence
Outpatients
Nursing care
RESUmEn 
Se objetivó verificar la adhesión de afecta-
dos por transtorno afectivo bipolar (TAB) a 
la terapéutica medicamentosa e identificar 
posibles causas de adhesión y no adhesión, 
de acuerdo al perfil fármaco-terapéutico. 
Estudio transversal, descriptivo, realizado 
en Núcleo de Salud Mental de municipio del 
interior paulista. Participaron 101 pacien-
tes con TAB. Datos recolectados mediante 
entrevista estructurada y test de Morisky-
Green, analizados con software Statitistical 
Package for the Social Science. Los resul-
tados demostraron que la mayoría (63%) 
de los sujetos investigados no adhiere a la 
medicación. A pesar de no haberse determi-
nado diferencias significativas entre el gru-
po de adherentes y no adherentes para las 
variables investigadas, fue posible verificar 
la utilización de polifarmacoterapia y regí-
menes terapéuticos complejos en el trata-
miento del TAB. Permanece como desafío la 
implementación de estrategias que puedan 
mejorar en la práctica la adhesión del pa-
ciente al tratamiento medicamentoso.
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intRodUction
Bipolar affective disorder (BAD) is a multifactorial and 
chronic illness, associated with important negative effects 
on patients’ quality of life(1). It is characterized by important 
mood swings between the extremes of euphoria (mania) 
and depression(2). Maniac episodes strongly tend to recur. 
Although research on the diagnosis, epidemiology, 
neurobiology and treatment of BAD has increased in re-
cent years, patients in the broad bipolar spectrum are still 
sub-diagnosed and treated inadequately(3). Among the 
costs of this disorder, the financial, psychological and so-
cial costs for patients as well as society stand out(4). 
It is a fact that BAD contains a strong biological com-
ponent and, thus, its main treatment form involves mood 
stabilizers(5). Patients are chronic and adherence to drugs 
therapy is fundamental to increase the chance of a better 
prognosis.
Studies on adherence in chronic illnesses, 
however, demonstrate that patients stop or 
do not even start taking the drugs because 
they consider their effects unsatisfactory or 
have experienced their collateral effects(6-7).
Non-adherence to the medication sub-
stantially limits treatment efficacy and can 
cause greater relapse, mental health emer-
gency service and hospitalization rates(8). It 
is highlighted that non-adherence to medi-
cation therapy is characterized by the diver-
gence between the medical prescription and 
the patient’s behavior. This phenomenon 
is subject to different factors’ influences, 
which directly affect the patients because 
they determine their behavior towards the 
recommendations related to their disease 
treatment. Among these factors, those re-
lated to the therapeutics can be mentioned.
Due to the complexity involves in the adherence phe-
nomenon, health professionals should equally take into 
account all related factors(6).
In a literature review(9) in MEDLINE (1966-2004), us-
ing the descriptors adhesion or adherence or compliance 
and treatment and bipolar, 16 titles were identified, with 
outcomes related to treatment adherence in BAD, none 
of which was developed in Brazil. Thus, the need for re-
search is highlighted, as well as monitoring and assess-
ment of patients’ prescribed medication use.
The above context also appoints the need to enhance, 
in health services, actions that contribute to prevent 
problems in BAD patients deriving from inadequate medi-
cation use. Knowing the factors involved in medication 
treatment monitoring will permit testing interventions 
that improve adherence and, perhaps, control of the dis-
order and consequent re-hospitalizations. 
This study aimed to verify BAD patients’ adherence to 
prescribed medication treatment, through the application 
of the Morisky-Green Test (MGT)(10) and to identify possible 
causes of medication adherence and non-adherence, ac-
cording to the variables related to the drugs therapy profile.
mEtHod
This cross-sectional and descriptive research was de-
veloped at a Mental Health Center (MHC) affiliated with 
the Unified Health System, located in an interior city in 
São Paulo State. Approval was obtained from the Institu-
tional Review Board (Protocol No. 0206/CEP-CSE-FMRP-
USP). Participants signed the informed consent term in 
compliance with National Health Council Resolution (CNS 
196/96). All 101 patients participated who had a medical 
appointment scheduled at the MHC within one year after 
the start of the data collection participated and complied 
with the following inclusion criteria: diagnosed with BAD, 
established by a physician responsible for the outpatient 
diagnosis; prescribed medication for contin-
uous use; age of 18 years or older and able 
to communicate verbally in Portuguese.
For data collection, the structured in-
terview technique was used. With a view 
to guaranteeing that all patients received 
standardized questions, a script was used 
with the subjects’ identification data (gen-
der, age, education, among others) and 
identification data of their drugs treatment 
profile (number of medication types used, 
total number of pills taken per day, number 
of times per day the medication is taken, 
among others). Adherence levels were de-
termined through the application of the 
Morisky-Green test(10). This test permits 
identifying the patient’s adherence level 
and distinguish whether non-adherence 
is due to intentional (questions: when you feel good, do 
you sometimes not take your medication? and when you 
feel bad taking the medication, do you sometimes not 
take it?), or non-intentional behavior (questions: do you 
sometimes forget to take your medication? and are you 
sometimes careless with the time you take your medica-
tion?). Previous studies have demonstrated the utility of 
this instrument and established its validity(10-12).
The interviews were held with the patients at the 
MHC. When the patient could not attend the institution 
for the interview, it was held at the patient’s home, on a 
pre-established date and time. 
The quantitative approach was used for data analysis. 
After applying the instrument, data were typed in a struc-
tured database in the format of an Excel worksheet. After 
typing and printing the first simple frequency list, coding 
errors or typos were verified and corrected. Then, the 
data were transported for analysis in Statistical Package 
for the Social Sciences (SPSS), version 11.5. Also, statisti-
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cal associations between the dependent and independent 
variables were investigated, using the chi-square test (χ2). 
The association hypothesis was accepted when p<0.05.
RESULtS 
Study subject characteristics
In the study period, 101 patients diagnosed with BAD 
had a medical appointment scheduled at the place of 
study. All of them accepted to participate in the study. 
Table 1 displays the study participants’ characteristics.
Table 1 shows that the most (70.3%) of the inter-
viewed patients were female, with a higher frequency in 
the age range from 41 to 50 years (31.8%). Also, higher 
percentages of patients were married (44.6%) and retired 
(23.8%). Nevertheless, the high percentages of single 
(30.7%) and separated/divorced patients (11.9%) stand 
out, all of whom divorced after the appearance of the 
BAD. As for diagnosis time, most of the patients (68.4%) 
had been diagnosed for up to ten years, and a large per-
centage (26.7%) for more than 15 years. Concerning oc-
cupation, only 14.8% of the interviewees had a fixed job 
contract and 23.8% had retired due to the disorder. 
Adherence to the medication treatment
Through the application of the Morisky-Green(10) test, 
it was identified that, out of 101 interviewed BAD pa-
tients, the majority (63%) does not adhere to the medica-
tion treatment.
Table 2 presents the subjects’ distribution regarding 
medication adherence and the number of medication 
types, total pills taken per day and number of times per 
day they take the medication.
Table 1 – Distribution of study subjects according to socio-demo-
graphic characteristics and diagnosis time
VARIABLE N %
Gender
Female 71 70.3
Male 30 29.7
Total 101 100
AGE
20–30 years 15 14.8
31–40 years 18 17.8
41–50 years 32 31.8
51–60 years 22 21.8
61–70 years 14 13.8
Total 101 100
MARITAL STATUS
Married 45 44.6
Single 31 30.7
Widowed 06 5.9
Separated/divorced 12 11.9
Fixed partner 06 5.9
Others 01 1.0
Total 101 100
DIAGNOSIS TIME’
0–05 years 40 39.7
06–10 years 29 28.7
11–15 years 10 9.9
16–20 years 07 6.9
21 years or more 10 9.9
Does not know 05 4.9
Total 101 100
OCCUPATION
Retired 24 23.8
Unemployed 11 10.9
Worker on a fixed contract 15 14.8
Autonomous worker 12 11.9
Housewife 21 20.8
Others 18 17.8
Total 101 100
Table 2 – Distribution of study subjects according to medication adherence and drugs therapy profile variables
PR=prevalence rate (95%CI); #=confidence interval; +p-test chi-square; **3 times per day – reference category
Drugs-related variables
Adherence
PR1(95%CI)# +pYes No Total
n (%) n (%) n (%)
Total number of pills  
taken per day
1 to 5 24 (34.3) 46 (65.7) 70 (100)
6 to 10 13 (41.9) 18 (58.1) 31 (100)
Total 37 (36.6) 64 (63.4) 101 (100) 0.81(0.48-1.38) 0. 462
Number of times per day 
medication is taken
1 04 (44.4) 05 (55.6) 09 (100) 1.47(0.62-3.47) 0. 505
2 20 (40.8) 29 (59.2) 49 (100) 1.35 (076-2.37)
3** 13 (30.2) 30 (69.8) 43 (100)
Total 37 (36.6) 64 (63.4) 101 (100)
Number of medication  
types used
1 08 (38.1) 13 (61.9) 21 (100)
2 or + 29 (36.3) 51 (63.8) 80 (100)
Total 37 (36.6) 64 (63.4) 101 (100) 1.05(0.56-1.94) 0. 876
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Table 2 reveals that no significant association existed 
between medication adherence and the variables: total 
number of pills taken per day, number of times per day 
medication is taken and number of medication types 
used. Some data related to these variables are clinically 
relevant and should be presented in further detail though, 
as follows.
Figure 1 displays the study subjects’ distribution ac-
cording to the number of medication types used.
It is observed in Figure 2 that most patients (44.5%) 
take between 3 and 4 pills per day. It is highlighted that 
almost half of the interviewed subjects (41.6%) take 5 or 
more pills per day. 
Figure 3 shows the study subjects’ distribution ac-
cording to the number of times per day they take the pre-
scribed drugs.
Figure 1 shows that, to most of the study participants 
(61.4%), 2 or 3 medication types were prescribed, with 
two drugs as the highest frequency for 36 patients. It 
should be highlighted that the prescriptions, provided by 
the physicians at the place of study, only contained psy-
chotropic drugs, so that only these drugs were considered 
in the present study. Thus, it is highlighted that 4 types of 
drugs (psychotropic drugs) were prescribed to 16 partici-
pants for home use. 
Figure 2 shows the subjects’ distribution according to 
the total number of pills taken per day.
Figure 1 – Distribution of study subjects according to total num-
ber of medication types taken per day
Figure 2 – Distribution of study subjects according to total num-
ber of pills taken per day
Figure 3 – Study subjects’ distribution according to the number 
of times per day they take medication
0
10
20
30
40
50
60
1 2 3
Number of types per day to take medication
F
re
q
u
e
n
c
y
Frequency
Figure 3 reveals that most (48.5%) of the participants 
take their medication twice a day. 
diScUSSion
Concerning the study subjects’ characteristics, it was 
identified that most of them were female. Literature ap-
points that no significant gender differences are observed 
in bipolar disorder(13). What can explain the large number 
of women attended at this health service, however, is the 
fact that men with bipolar affective disorder seek medical 
care significantly less than women(13).
As for the high percentage of single (30.7%) and sepa-
rated/divorced (11.9%) patients, a study reveals that the 
divorce rate among people with BAD is approximately two 
to three times higher in comparison with individuals with-
out the disease(14). About 50% of all partners reported that 
they would not have married or had children with the pa-
tients if they know they had a mood disorder(2).
With regard to the diagnosis time, most patients 
(68.4%) have been diagnosed for up to ten years and many 
(26.7%) for more than 15 years. Identifying the start age 
of the bipolar affective disorder represents a clinical chal-
lenge. It is essential, especially at the start of treatment, to 
establish a high-quality therapeutic alliance with the pa-
tients, as this aspect will facilitate their introduction to, ac-
ceptance of and adherence to preventive treatment(15). 
In this study, only 14.8% of the interviewed people 
had a formal job. In the specific case of bipolar affective 
disorder, a study(16) demonstrated that, despite the high 
unemployment rate among people with this diagnosis, 
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they strongly want to keep their job and display high aca-
demic performance levels, comparing themselves with 
people with other affective disorder types. This study(16) 
reveal that, when they do not have symptoms of the disor-
der, BAD patients are capable of keeping up a good perfor-
mance at work. Medication side effects and crisis episodes 
during work represent the main negative influences on its 
maintenance. Therefore, employers need to be sufficiently 
flexible and sensitive to changes in these people’s needs, 
offering different support levels at different times(16).
In this context, health professionals are responsible 
for working in articulation with the community, involving 
non-governmental organizations, social solidarity institu-
tions, among others, so as to encourage and help patients 
in their socio-professional reintegration. They should also 
orient patients about signs appointing the start of a cri-
sis in the disorder and to recognized, at work, the change 
processes that can precipitate the appearance of symp-
toms, preventing relapses. 
As for medication treatment adherence, it is highlight-
ed that most interviewed BAD patients (63%) do not ad-
here. Non-adherence rates can increase the reoccurrence 
of mania and crisis experiences. These constitute one of 
the causes associated with rehospitalization and suicide(17). 
In this respect, a bibliographic study on people’s ad-
herence/non-adherence to health treatment showed that 
conceptions on the issue in research revealed a limited per-
spective on the patients’ role in their treatment process, 
considering them submissive to professionals and health 
services, as opposed to active subjects in their process of 
living with the disorder and treatment. The same study re-
vealed that patients receive the greatest burden of respon-
sibility for treatment adherence/non-adherence, while 
professionals and health services need to be co-responsible 
in this process(18). Hence, the recurring idea is that patients 
should follow and comply with health professionals’ recom-
mendations and that their behavior should coincide with 
medical indications. When they fail to observe these indi-
cations, they are considered non-adherent to treatment(18).
In view of the complexity of the medication treatment 
adherence process, mental health professionals need pro-
found knowledge on different therapeutic modes, as the 
approach of this problem, through an exclusively biologi-
cal or psychological view, may not attend to patients’ ac-
tual demands. 
To effectively act on problems related to non-adher-
ence to treatment, health professionals need to know the 
reasons that make patients not adhere to the treatment, 
as well as their conceptions about the prescribed medica-
tion. In this respect, a study(19) appoints that, to promote 
patients’ health-related behavioral changes, such as treat-
ment adherence, health professionals need to evoke pa-
tients’ good motivations. 
Concerning the drugs therapy profile of the patients 
under analysis, it was verified that, for most of them, two 
to three types of medication were prescribed. It should be 
highlighted that four psychotropic drugs were prescribed 
to 16 of them for use at home. 
As different phases characterized BAD, some agents 
may be effective in one phase of the disorder only. Poly-
pharmacy is frequently used to treat persistent subsyn-
dromic symptoms after monotherapy has failed(20).
Thus, monotherapy is an exception instead of a rule 
in BAD cases, which is one of the main difficulties for pa-
tients’ treatment adherence(21). It is also known that the 
simultaneous prescription of various drugs as a therapeu-
tic strategy and the growing number of these agents in 
the market can contribute to enhance the beneficial ef-
fects of therapy, but can also result in unwanted effects 
and medication interactions. Concerning psychotropic 
drugs, especially antipsychotics, some of their collateral 
effects are painful and even disabling, which can consti-
tute a bottleneck for patients’ adherence(22).
In this study, almost half of the interviewees take five 
or more pills per day. The number of drugs taken per day 
can interfere in adherence due to the greater probability 
of side effects, besides intake difficulties. For each pill tak-
en, the risk of non-adherence increases by 12%(23).
In this respect, in another study(24), it was identified 
that there are BAD patients who, in the belief that they 
are taking a lot of medication, tend to question the ac-
tual need for the prescribed doses, as well as their abil-
ity to support these doses. Friends and relatives’ opinions 
reinforce this belief, who stimulate non-adherence to the 
medication. This study also found that, in view of these 
situations, BAD patients feel the need to be submitted to 
a strict and individual assessment by the health team con-
cerning the established medication therapy, so as to feel 
safer. Nurses play a fundamental role in the welcoming 
and orientation of these clients.
It is very important for the health team to prioritize 
drugs that interfere as little as possible in the patient’s life 
habits and facilitate the automation of medication intake 
in a personalized way, associating them with daily activi-
ties like breakfast, reading the newspaper, television pro-
grams etc., with a view to avoiding forgetting, especially in 
complex therapies that involve various medication types 
and a large number of daily doses.
concLUSion
These research results point towards a patient sample 
with low medication adherence levels. Although no signifi-
cant differences were found between the group of adherent 
and non-adherent patients concerning the research vari-
ables, it could be verified that, in BAD, monotherapy is really 
an exception instead of a rule and that patients are submit-
ted to complex therapeutic regimens, involving the intake 
of various pills per day. It should be highlighted that, in this 
study, only psychotropic drugs were considered, underesti-
691Rev Esc Enferm USP2012; 46(3):686-91 www.ee.usp.br/reeusp/
Bipolar affective disorder: pharmacotherapeutic 
profile and adherence to medication
Miasso AI, Carmo BP, Tirapelli CR
correspondence addressed to: adriana inocenti miasso
campus da usp 
avenida dos bandeirantes, 3900 - monte alegre
cep 14040-902 - ribeirão preto, sp, brazil
mating this complexity in patients with comorbidities who 
use other medication classes for treating these problems.
Putting in practice strategies that can improve the ad-
herence of BAD patients to medication treatment in prac-
tice remains a challenge. Educative approaches that con-
sider patients as the center of the care process, allowing 
them to expose their treatment-related doubts, anxieties, 
difficulties, opinions and experiences can represent an im-
portant measure to minimize non-adherence.
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